Halozyme Therapeutics, Inc. (HALO)
75.85
+0.80
(+1.07%)
USD |
NASDAQ |
Jul 15, 16:00
75.89
+0.04
(+0.05%)
After-Hours: 20:00
Halozyme Therapeutics Price : 75.85 for July 15, 2026
Price Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 14, 2026 | 75.24 | 75.80 | 74.00 | 75.05 | 1.784M |
| Jul 13, 2026 | 75.94 | 76.99 | 74.52 | 76.11 | 1.823M |
| Jul 10, 2026 | 78.82 | 79.19 | 75.33 | 76.20 | 1.474M |
| Jul 09, 2026 | 80.44 | 81.94 | 78.33 | 78.62 | 1.783M |
| Jul 08, 2026 | 79.96 | 80.84 | 78.67 | 80.37 | 2.487M |
| Jul 07, 2026 | 81.50 | 82.26 | 80.61 | 81.57 | 2.037M |
| Jul 06, 2026 | 79.17 | 81.01 | 78.22 | 80.78 | 2.505M |
| Jul 02, 2026 | 77.85 | 79.51 | 77.54 | 79.45 | 1.566M |
| Jul 01, 2026 | 78.47 | 78.50 | 75.71 | 77.01 | 1.782M |
| Jun 30, 2026 | 77.46 | 78.95 | 77.19 | 78.27 | 1.944M |
| Jun 29, 2026 | 75.00 | 77.24 | 74.47 | 77.18 | 2.237M |
| Jun 26, 2026 | 72.96 | 76.32 | 72.71 | 74.96 | 2.872M |
| Jun 25, 2026 | 71.38 | 73.53 | 71.38 | 72.64 | 1.457M |
| Jun 24, 2026 | 70.12 | 71.87 | 69.72 | 71.15 | 1.946M |
| Jun 23, 2026 | 69.38 | 70.21 | 68.93 | 69.62 | 2.716M |
| Jun 22, 2026 | 69.34 | 69.81 | 68.27 | 68.99 | 1.054M |
| Jun 18, 2026 | 69.24 | 69.24 | 67.02 | 68.55 | 3.654M |
| Jun 17, 2026 | 69.64 | 70.39 | 68.18 | 68.57 | 1.567M |
| Jun 16, 2026 | 71.61 | 72.25 | 67.94 | 69.64 | 1.950M |
| Jun 15, 2026 | 69.95 | 71.98 | 69.30 | 71.28 | 1.816M |
| Jun 12, 2026 | 71.01 | 71.80 | 69.32 | 69.50 | 1.042M |
| Jun 11, 2026 | 70.66 | 71.12 | 70.26 | 70.73 | 1.344M |
| Jun 10, 2026 | 71.68 | 72.19 | 70.25 | 70.50 | 1.947M |
| Jun 09, 2026 | 71.99 | 72.29 | 70.24 | 71.48 | 1.318M |
| Jun 08, 2026 | 71.59 | 71.92 | 70.62 | 70.73 | 1.498M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Agenus, Inc. | 5.015 |
| Altimmune, Inc. | 2.985 |
| Lineage Cell Therapeutics, Inc. | 1.225 |
| Vertex Pharmaceuticals, Inc. | 477.00 |
| Amgen, Inc. | 358.25 |
Price Related Metrics
| PE Ratio | 27.28 |
| PS Ratio | 6.122 |
| Price to Book Value | 40.93 |
| Price to Free Cash Flow | 13.83 |
| Earnings Yield | 3.67% |
| Market Cap | 8.990B |
| Operating PE Ratio | 10.75 |
| Normalized PE Ratio | 15.55 |